An overview of the research to date and the ways in which such evidence can be used to guide the treatment of patients was presented at the 2019 ACR/ARP Annual Meeting in a session titled Optimizing Outcomes in Psoriatic Arthritis: A Domain-Based Strategy. In the years since this presentation, additional research has helped supply greater… [Read More]
As insurers phase out pandemic-related flexibilities, many are raising new obstacles to try to limit their financial exposure.... [Read More]
Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.... [Read More]
The ACR Review Course featured eight talks providing a practical review of issues encountered by rheumatologists.... [Read More]
Recent research examined the use of apremilast in patients with psoriatic arthritis using the Clinical Disease Activity in Psoriatic Arthritis (cDAPSA) measurement. The findings suggest patients with moderate disease activity at baseline benefit most from the treatment…... [Read More]
Hair dye products are commonly used by both men and women to enhance youth and beauty and to follow fashion trends. As reported in the medical literature, hair dyes and their ingredients are associated with allergic contact dermatitis. A possible association with joint inflammation has also been recognized. There is literature to support that para-phenylenediamine… [Read More]
ATLANTA—As many rheumatologists will recall, it was not too long ago that psoriatic arthritis was regarded somewhat like “rheumatoid arthritis with a rash,” with little attention paid to the ways in which the unique pathophysiology and manifestations of this entity make it distinct from other forms of inflammatory arthritis. At the 2019 ACR/ARP Annual Meeting… [Read More]
The Scottish Medicines Consortium has released a detailed advice document recommending risankizumab for treating adults with psoriasis…... [Read More]
Three clinical experts on gout offer their insights into common management errors, clinical pearls, new safety data from the FDA and the role of biologic therapies in the management of gout.... [Read More]
Psoriatic arthritis came to be viewed as a distinct disease entity with specific clinical features, genetics and pathophysiology only gradually. One important historic development in this transition was a 1973 paper written by a pair of researchers out of Leeds, England: John M. Moll, BSc, DM, and Verna Wright, MD, FRCP.1 Here we discuss the… [Read More]